Chr. Hansen Holding A/S
CRTSF
Other OTC79.30
USD
+4.30
- -
ISIN
DK0060227585
Return %
Stock
S&P500
1Y
8.90
17.85
3Y
-22.97
64.56
5Y
-9.89
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Mauricio Graber
- Full Time Employees
- 3,834
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- Boege AllE 10-12 Horsholm Denmark 2970
- IPO Date
- May 15, 2012
- Website
- chr-hansen.com
- Similar Companies
- Business
- Chr. Hansen Holding A/S is a global bioscience company headquartered in Hørsholm, Denmark, specializing in the development, production, and marketing of natural ingredients including bacterial cultures, enzymes, probiotics, and natural colors. The company's core products serve diverse sectors such as food processing, beverages, dietary supplements, pharmaceuticals, agricultural products, and animal feed. These products encompass categories like dairy and meat cultures, fermentation solutions, plant health ingredients, probiotics for human and animal health, and natural colors used in a variety of foods, confectionery, and beverages. Founded in 1874, Chr. Hansen operates internationally with production sites in Denmark, Germany, France, and the United States, and maintains a presence in over 30 countries. In a major strategic change, Chr. Hansen completed a merger with Novozymes A/S in January 2024, forming a new bioscience entity named Novonesis. This merger aims to leverage combined innovations in natural ingredient solutions across food, nutritional, pharmaceutical, and agricultural industries with a focus on promoting healthier living, sustainable food production, and climate-neutral practices. Additionally, Chr. Hansen continues to strengthen its technology platform through acquisitions and R&D partnerships, particularly in areas like microbial cultures, dairy enzymes, probiotics, bioprotection, plant health, and fermented plant-based ingredients. In late 2023, part of the company's lactase enzyme business was divested to Kerry Group, enhancing focus on core bioscience offerings. Chr. Hansen’s innovation is supported by a vast microbial strain portfolio and robust R&D activities primarily based in Denmark. The company's products are distributed worldwide with significant market presence across Europe, the Americas, and Asia-Pacific. Chr. Hansen targets food manufacturers, pharmaceutical producers, agricultural businesses, and dietary supplement companies, aiming to provide natural, sustainable, and functional solutions to complex bioscience challenges. In summary, Chr. Hansen Holding A/S is a historic and leading bioscience firm producing cultures, enzymes, probiotics, and natural colors for food and health applications, recently merged into Novonesis to expand its global biosolution capabilities while focusing on sustainable and innovative ingredient technologies for diverse industrial applications.